Spartan Fund Management’s BioPlus Acquisition Corp. Class A Ordinary Shares BIOS Stock Holding History

Spartan Fund Management’s Portfolio BIOS Stock Details BIOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-160,316	Closed	-$1.71M	–	345
2023 Q2	$1.71M	Buy	+160,316	New	+$1.69M	0.83%	47
2023 Q1	–	Sell	-74,485	Closed	-$763K	–	427
2022 Q4	$763K	Sell	74,485 -74,800	-50%	-$759K	0.28%	128
2022 Q3	$1.5M	Buy	+149,285	New	+$1.49M	0.46%	85

Other funds holding BIOS

WCMNY

Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return

WRBC

W.R. Berkley Corp Greenwich, Connecticut $2.18B AUM 13.58% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return

Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return

RCM

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

MSU

Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Spartan Fund Management's BIOS Position: Q3 2023 in Review

Spartan Fund Management sold out of BioPlus Acquisition Corp. Class A Ordinary Shares (BIOS) in Q3 2023, closing a stake of 160,316 shares — an estimated $1.71M sold.

Spartan Fund Management first reported a position in BIOS in Q3 2022 and held it in 3 quarters. The position peaked at $1.71M in Q2 2023. 30 funds tracked by Wall St. Rank hold BIOS as of Q3 2023.

Spartan Fund Management reported no remaining BioPlus Acquisition Corp. Class A Ordinary Shares position as of Q3 2023 after selling out during the quarter.
Spartan Fund Management sold 160,316 BioPlus Acquisition Corp. Class A Ordinary Shares shares in Q3 2023, an estimated $1.71M.
Spartan Fund Management first reported a position in BioPlus Acquisition Corp. Class A Ordinary Shares in Q3 2022 and held it in 3 quarters.
Spartan Fund Management's BioPlus Acquisition Corp. Class A Ordinary Shares position peaked at $1.71M in Q2 2023.
30 funds tracked by Wall St. Rank held BioPlus Acquisition Corp. Class A Ordinary Shares as of Q3 2023.

Based on Spartan Fund Management's 13F filing for Q3 2023, filed 23 Oct 2023.